Regulus Therapeutics INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
Regulus Therapeutics Inc. director William H. Rastetter has disposed of his common stock and derivative securities as the company completed its merger, becoming a wholly-owned subsidiary of Novartis AG.
Pascale Witz, a Director of Regulus Therapeutics Inc., has reported the disposition of all her beneficial ownership in the company's securities, effective June 25, 2025, due to the completion of the merger with Novartis AG.
Regulus Therapeutics Inc. has been acquired by Redwood Merger Sub Inc., a Novartis AG subsidiary, resulting in the disposition of all common stock, options, and warrants held by Director Stelios Papadopoulos in exchange for cash and contingent value rights.
A recent SEC Form 4 filing reveals that Hugh Rosen, a Director at Regulus Therapeutics Inc., has disposed of all his common stock, restricted stock units, and stock options as a result of the company's acquisition by Novartis AG.
Form 4: Regulus Therapeutics Insider Disposes All Holdings Following Novartis Acquisition Completion
Preston Klassen, President and Head of R&D at Regulus Therapeutics Inc., has disposed of all his common stock, performance stock units, and stock options following the completion of the company's acquisition by Novartis AG.
A senior executive at Regulus Therapeutics Inc. has filed a Form 4 detailing the conversion of his equity holdings into cash and contingent value rights as a result of the company's acquisition by Novartis AG.
Joseph P. Hagan, CEO and Director of Regulus Therapeutics Inc., has disposed of all his beneficial ownership in the company following its acquisition by Novartis AG, converting shares, options, PSUs, and warrants into cash and contingent value rights.
David Baltimore, a Director of Regulus Therapeutics Inc., has disposed of all his direct and indirect beneficial ownership in the company following its acquisition by Novartis AG for $7.00 cash per share plus a contingent value right.
A recent SEC Form 4 filing reveals Regulus Therapeutics Inc. Director Jason Raleigh Nunn has disposed of all his common stock and stock options in the company, effective June 25, 2025, as a direct result of the company's acquisition by Novartis AG.
Form 4: Regulus Therapeutics Director Reports Full Share and Option Disposal Following Novartis Acquisition
A director of Regulus Therapeutics Inc. has reported the complete disposal of all common stock and stock options following the company's acquisition by Novartis AG, which closed on June 25, 2025, for $7.00 cash plus a contingent value right per share.
Director Kathryn J Collier reports disposition of shares and options as Regulus Therapeutics Inc. completes its merger with a Novartis AG subsidiary for $7.00 cash per share plus a contingent value right.
Regulus Therapeutics Inc.'s Chief Financial Officer, Crispina Calsada, has reported the disposition of all her common stock, performance stock units, and stock options following the completion of the acquisition by Novartis AG.
A director at Regulus Therapeutics Inc. exercised stock options, acquiring 6,325 common shares, but their overall direct beneficial ownership decreased following the transactions.
Preston Klassen, President & Head of R&D and Director at Regulus Therapeutics Inc. (RGLS), has acquired 12,000 shares of common stock, signaling increased insider confidence.
Director Stelios Papadopoulos acquired 62,500 restricted stock units in Regulus Therapeutics Inc., according to a Form 4 filing.
Director David Baltimore received 62,500 Restricted Stock Units from Regulus Therapeutics, vesting monthly over 12 months.
Director Jason Nunn of Regulus Therapeutics Inc. was granted 62,500 restricted stock units on April 30, 2025, vesting monthly over 12 months.
Alice Shih-hou Huang, a director at Regulus Therapeutics, reports the acquisition of restricted stock units.
Director Pascale Witz reports the acquisition of 62,500 restricted stock units in Regulus Therapeutics.
Director Kathryn J. Collier of Regulus Therapeutics Inc. reports the acquisition of 62,500 restricted stock units.
Director Rosen Hugh of Regulus Therapeutics Inc. reports acquisition of 62,500 restricted stock units.
Director William H. Rastetter received 62,500 Restricted Stock Units in Regulus Therapeutics Inc.
Regulus Therapeutics CEO, Joseph P. Hagan, acquired 50,000 shares and 1,350,000 stock options in a recent transaction.
Preston Klassen, President & Head of R&D at Regulus Therapeutics, was granted 675,000 stock options.
Director David Baltimore of Regulus Therapeutics Inc. purchased 19,610 shares of common stock at an average price of $1.06 per share.
Christopher Aker, Senior VP & General Counsel at Regulus Therapeutics, was granted stock options for 487,500 shares.
Regulus Therapeutics' Chief Financial Officer, Crispina Calsada, has been granted 562,500 stock options, which vest over a 48-month period.
Christopher Aker, Sr. VP & General Counsel of Regulus Therapeutics Inc., sold shares of common stock to cover tax withholding obligations related to vesting Restricted Stock Units (RSUs) under a pre-existing 10b5-1 plan.
Regulus Therapeutics CEO Joseph P Hagan sold shares of common stock on January 13 and 14, 2025, to cover tax withholding obligations related to vesting Restricted Stock Units (RSUs).
Crispina Calsada, CFO of Regulus Therapeutics, sold shares to cover tax withholding obligations related to vesting Restricted Stock Units (RSUs) under a pre-existing 10b5-1 plan.